Reports FY25 revenue $17.2M vs. $5.9M last year. Mesoblast (MESO) CEO Dr. Silviu Itescu said, “This has been a banner year for the Company, with achievement of FDA approval for Ryoncil, the first and only FDA approved mesenchymal stromal cell, MSC, product in the United States and a successful commercial launch of the product for treatment of steroid-refractory acute graft-versus-host disease in pediatric patients aged 2 months and older. We are working tirelessly to transform Mesoblast into a fast-paced commercial biotechnology company with demonstrable sales of our first commercial product Ryoncil. We intend to deliver additional approved indications for sales of Ryoncil and to launch a next-generation platform technology into potential blockbuster indications including heart failure and chronic low back pain.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MESO:
- Mesoblast options imply 11.6% move in share price post-earnings
- Mesoblast downgraded to Hold from Buy at Jefferies
- Mesoblast reports Q1 Ryoncil gross revenue $13.2M
- Mesoblast Announces Cessation of Securities and Capital Adjustments
- Buy Rating for Mesoblast: FDA Alignment and Promising Revascor Data Drive Optimism